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Abstract
Background: The ‘Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug
Administration In Cardiac Arrest’ (PARAMEDIC2) trial showed that adrenaline improves overall survival, but not
neurological outcomes. We sought to determine the within-trial and lifetime health and social care costs and
benefits associated with adrenaline, including secondary benefits from organ donation.
Methods: We estimated the costs, benefits (quality-adjusted life years (QALYs)) and incremental cost-effectiveness
ratios (ICERs) associated with adrenaline during the 6-month trial follow-up. Model-based analyses explored how
results altered when the time horizon was extended beyond 6 months and the scope extended to include
recipients of donated organs.
Results: The within-trial (6 months) and lifetime horizon economic evaluations focussed on the trial population
produced ICERs of £1,693,003 (€1,946,953) and £81,070 (€93,231) per QALY gained in 2017 prices, respectively,
reflecting significantly higher mean costs and only marginally higher mean QALYs in the adrenaline group. The
probability that adrenaline is cost-effective was less than 1% across a range of cost-effectiveness thresholds.
Combined direct economic effects over the lifetimes of survivors and indirect economic effects in organ recipients
produced an ICER of £16,086 (€18,499) per QALY gained for adrenaline with the probability that adrenaline is cost-
effective increasing to 90% at a £30,000 (€34,500) per QALY cost-effectiveness threshold.
Conclusions: Adrenaline was not cost-effective when only directly related costs and consequences are considered.
However, incorporating the indirect economic effects associated with transplanted organs substantially alters cost-
effectiveness, suggesting decision-makers should consider the complexity of direct and indirect economic impacts
of adrenaline.
Trial registration: ISRCTN73485024. Registered on 13 March 2014.
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Introduction
Although survival rates following adult out-of-hospital
cardiac arrest have increased in recent years, they gener-
ally remain below 10% [1, 2]. Survivors are at increased
risk of cognitive and functional impairment and often
take significant time to attain an acceptable quality of
life or to return to work [3].
In some countries, when a patient dies after cardiac ar-
rest, families can be asked to agree to the patient’s or-
gans being donated for the benefit of others. A meta-
analysis of 26 studies reported that, on average, 5.8%
(95% CI 2.1–10.9%) of patients admitted to intensive
care donate their organs for transplantation after brain
stem death [4]. Observational studies suggest that car-
diac arrest before organ donation does not adversely
affect long-term graft function [5] and that such trans-
plant programmes are cost-effective [6, 7].
The PARAMEDIC2 (Prehospital Assessment of the
Role of Adrenaline: Measuring the Effectiveness of Drug
Administration In Cardiac Arrest) trial showed that
adrenaline improves overall survival, but not long term
neurological outcome [8, 9]. In this paper, we explore
the costs and benefits of adrenaline within the PARAME
DIC2 trial across within-trial and lifetime horizons and
model the contribution of organ donation after a cardiac
arrest on cost-effectiveness.
Methods
Trial background
PARAMEDIC2 (ISRCTN73485024) was a pragmatic, in-
dividually randomised, double-blind, controlled trial of
8014 adult patients with out-of-hospital cardiac arrest in
the UK [9]. Patients, treated by five National Health Ser-
vice (NHS) ambulance services between December 2014
and October 2017, were randomised to either parenteral
adrenaline or saline placebo, along with standard care.
The primary clinical outcome was the rate of survival at
30 days. Survival, neurological outcomes as indicated by
the modified Rankin Scale (mRS) (ranging from 0 [no
symptoms] to 6 [death]) [10] and economic outcomes
were followed up from randomisation to 6 months. The
South Central–Oxford C Research Ethics Committee
(REC: 14/SC/0157) and the Medicines and Healthcare
Products Regulatory Authority (EudraCT: 2014-000792-
11) approved the study protocol. The trial was funded
by the UK National Institute for Health Research Health
Technology Assessment Programme (12/127/126). Fur-
ther details of the trial are reported elsewhere [9].
Overview of economic evaluation
A cost-utility analysis was conducted, with results
expressed in terms of incremental cost per quality-
adjusted life year (QALY) gained through the use of
adrenaline. The baseline economic evaluation was
conducted from the perspective of the UK NHS and per-
sonal social services (PSS) [11], with a time horizon of
6 months post-randomisation. A decision-analytic model
was used to extrapolate outcomes beyond trial follow-up
and assess the cost-effectiveness of adrenaline over a
lifetime horizon. All costs were expressed in British
pounds sterling and valued at 2017 prices (with com-
mensurate values in Euros estimated using purchasing
power parities). Costs and QALYs accrued beyond the
first year of follow-up were discounted to present values
at 3.5% per annum in accordance with recommendations
from the National Institute for Health and Care Excel-
lence (NICE) [11]. The economic evaluation adhered to
an approved pre-specified analytical plan which is avail-
able in the supplementary material (Additional file 1).
Measurement and valuation of resource use
Resource inputs associated with the pre-hospital emer-
gency response, until the point of hospital admission or
death, were extracted from the trial case report forms
completed by research paramedics. These data included
the number of emergency response staff/ambulance
crew and vehicles in attendance, duration of emergency
response, and cumulative doses of adrenaline adminis-
tered. Unit costs for these resource inputs were drawn
from national tariffs (Additional file 2).
For patients surviving to hospital admission, the eco-
nomic costs associated with hospital care were extracted
through data linkage with two national population-wide
databases: Hospital Episode Statistics (HES) for England
and the Patient Episode Database for Wales (PEDW).
This provided patient-level profiles of resource use asso-
ciated with hospital episodes for study patients over the
trial time horizon, including emergency department at-
tendances, critical care and other inpatient admissions,
covering procedures undertaken including percutaneous
coronary intervention, by-pass surgery, implantable car-
dioverter defibrillators (ICDs), cardiac pacemakers and
lengths of stay, day case admissions and outpatient at-
tendances. HealthCare Resource Group (HRG) codes
were derived using the NHS HRG4 2016–17 Reference
Cost Grouper software version [12]. The Department of
Health and Social Care’s Reference Costs 2016–17 sched-
ule was used to assign costs to derived HRG codes [12].
For patients without linkage to routine hospital records,
hospital resource inputs were extracted from data con-
tained within the trial case report forms and valued
using national tariffs.
Surviving patients or their proxies were asked to
complete questionnaires at 3 and 6 months post-
randomisation, reporting hospital admissions and use of
hospital outpatient services following initial discharge,
by type and volume, and use of community health and
social services, medications and aids and equipment.
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Further questions captured wider societal attributable re-
source use, with data collected on time off work, over-the-
counter medications, aids and adaptations purchased pri-
vately and any additional costs borne by study patients or
informal carers. Unit costs for these resource inputs were
drawn from national tariffs (Additional file 2).
Calculation of health utilities and QALYs
Health-related quality of life was assessed using the
EuroQol EQ-5D-5L [13], completed at 3 and 6months
post-cardiac arrest. Responses to the EQ-5D-5L descrip-
tive system were converted into health utility values,
based on the UK EQ-5D-3L tariff using the van Hout in-
terim cross-walk algorithm [14], in line with current rec-
ommendations [15]. mRS scores collected at hospital
discharge were also converted into health utility values,
based on the UK EQ-5D-3L tariff, using a published
mapping algorithm [16]. A QALY profile was generated
for each trial participant using the area-under-the-curve
method, assuming a baseline health utility value of zero
[17] and linear interpolation between utility measure-
ments at hospital discharge and at 3 and 6months as-
sessment points, accounting for survival [18]. We used
3- or 6-month mRS-derived health utilities in place of
EQ-5D-5L-derived values if the latter were missing.
Analytical methods
Analyses of clinical outcomes, resource use and costs
Survival outcomes were analysed through the use of
fixed-effect regression models with adjustment for age,
sex, interval between the emergency call and the ambu-
lance arrival at the scene, interval between the ambu-
lance arrival and the administration of the study drug,
cause of cardiac arrest, initial cardiac rhythm, whether
the cardiac arrest was witnessed and whether CPR was
performed by a bystander [9]. Between treatment-group
differences in mean resource use and mean costs were
estimated using two-sample Student’s t tests. Estimates
of 95% confidence intervals (CIs) surrounding between-
group differences in mean costs were obtained using
nonparametric bootstrapping with replacement, based
on 1000 replications [19].
Handling missing data
Multiple imputations using chained equations with pre-
dictive mean matching [20] was used to predict values
for missing observations, assuming data were missing at
random. Missing costs and health utility values were im-
puted at the level of resource category, health-related
quality of life measure and assessment point, stratified
by survival status at hospital discharge and treatment al-
location in accordance with current recommendations
[21]. Twenty imputed datasets were generated and used
to inform the base-case and subsequent sensitivity and
subgroup analyses. Parameter estimates were pooled
across the 20 imputed datasets using Rubin’s rule to ac-
count for between and within-imputation components
of variance terms associated with parameter estimates.
Within-trial economic evaluation
Bivariate linear regressions that take into account the
correlation between each patient’s costs and effects were
used to model total costs and total QALYs over the 6-
month follow-up period. By specifying the treatment
group as an indicator within each equation, the incre-
mental costs and QALYs attributable to adrenaline were
estimated, while controlling for baseline covariates (age,
sex, time to first dose administration, cause of cardiac
arrest, whether the cardiac arrest was witnessed, whether
a bystander performed CPR and initial cardiac rhythm).
Cost-effectiveness was expressed in terms of an incre-
mental cost-effectiveness ratio (ICER), defined as the in-
cremental adjusted cost of adrenaline divided by the
incremental adjusted QALYs of adrenaline. The ICER
was then compared with a range of cost-effectiveness
threshold values for an additional QALY. ICERs falling
below or in the region of £20,000 (€23,000) to £30,000
(€34,500) per QALY gained would, in general, be consid-
ered as representing a cost-effective use of UK NHS re-
sources [11, 22]. Confidence intervals surrounding mean
ICER values were not calculated as they are problematic
to interpret if the ICER denominator is estimated close
to zero and the interval extends to cover negative values
[23]. This is because a negative ICER might equally
imply lower costs and more effective treatment or
greater costs and less effective treatment compared with
placebo. There is no way of differentiating between these
two qualitatively different scenarios from a confidence
interval alone. Thus, we followed standard practice in
economic evaluations to present mean ICER values with-
out accompanying confidence intervals or standard er-
rors. Instead, uncertainty surrounding mean cost-
effectiveness estimates were characterised through a
Monte Carlo method involving simulating 1000 repli-
cates of the ICER from a joint distribution of incremen-
tal costs and incremental QALYs [24]. By calculating net
monetary benefits for each of these simulated ICER
values at alternative cost-effectiveness thresholds varying
from £0 to £100,000 (€115,000) per QALY gained, the
probability of cost-effectiveness of adrenaline (defined as
the proportion of positive net monetary benefits at a
given threshold level) was calculated and plotted as a
cost-effectiveness acceptability curve [25].
Sensitivity analyses
A series of sensitivity analyses, summarised in Add-
itional file 3, assessed the impact of varying features of
the within-trial economic evaluation on cost-
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effectiveness. These included extending the perspective
of analysis to cover broader societal resource use and
costs and extending the time horizon to 12months after
the cardiac arrest event. Further economic modelling
(described in the sections that follow) explored how re-
sults altered when the time horizon was extended to
cover the lifetimes of cardiac arrest survivors and the
scope extended to include recipients of donated organs.
Sub-group analyses
A series of pre-specified subgroup analyses, summarised
in Additional file 4, explored whether the cost-
effectiveness estimates based on the within-trial data al-
tered by age, gender, time to first dose administration,
cause of cardiac arrest, whether the cardiac arrest was
witnessed, whether bystander performed CPR or initial
cardiac rhythm.
Extrapolations of cost-effectiveness
Controlled organ donation after neurological or cardiac
death is available to families for patients who sustain un-
survivable severe brain injury. Decision-analytic model-
ling was used to estimate the incremental cost-
effectiveness of adrenaline beyond the parameters of the
PARAMEDIC2 trial to include the costs and benefits of
organ donation. A Markov state transition model was
developed to extrapolate lifetime costs and benefits for
out-of-hospital cardiac arrest survivors (Fig. 1, plot a).
We separately adapted a previous economic model of
adult lung transplantation [26] to simulate the impact
on the cost-effectiveness of adrenaline resulting from
changes in organ donation from deceased PARAMEDI
C2 donors who had experienced out-of-hospital cardiac
arrest. The model (Fig. 1, plot b) simulated pre and
post-transplantation survival for individuals on the active
national transplant waiting list. Epidemiological data for
the model were informed by a separate linkage of the
PARAMEDIC2 patients to the UK National Transplant
Registry. Further details of the model structures, data in-
puts, analytical methods and description of methods for
integrating the direct and indirect effects of adrenaline
generated by the two models are provided in
Additional file 5.
Results
A total of 8014 patients were randomised to either
parenteral adrenaline (4015 patients) or saline placebo
(3999 patients). In the adrenaline group, 130 patients
(3.2%) were alive at 30 days, compared with 94 pa-
tients (2.4%) in the placebo group (unadjusted odds
of survival, 1.39; 95% confidence interval [CI], 1.06 to
1.82; P = 0.02) [9]. Severe neurologic impairment at
hospital discharge (mRS score of 4 or 5) was more
common amongst survivors in the adrenaline group
than in the placebo group (39 of 126 patients [31.0%]
vs. 16 of 90 patients [17.8%]) [9].
Figure 2 summarises the flow and completeness of
data sources used to inform the economic parameters of
the trial. Overall, between 1 and 2% of costs (at the com-
ponent level) and approximately 1% of QALY data were
missing (and subsequently imputed) for the primary
analysis.
Resource use reported by the trial participants and or
their proxies by treatment arm is summarised in Add-
itional file 6. More patients were admitted to intensive
care in the adrenaline arm (2016 vs 1209, P < 0.001),
Fig. 1 Model diagrams. Plot a: Model to extrapolate cost-effectiveness beyond PARAMEDIC2 trial follow-up. OHCA represents health state for out-
of-hospital cardiac arrest patients. Good represents survival with good neurological function. Poor represents survival with poor neurological
function. Plot b: Organ donor model adapted from Fisher et al. [26]
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creating a larger group for assessment for donation after
neurological or cardiac death. Linkage of the PARAME
DIC2 patients to the UK National Transplant Registry
revealed that there were 99 recipients of organs donated
by the adrenaline group compared with 67 recipients of
organs donated by the placebo group (from 40 donors in
the adrenaline group vs 24 donors in the placebo group).
Breakdown by organ type is provided in Table 1.
Amongst all participants, mean total NHS and PSS
costs over the 6-month trial time horizon was £3789
(€4357) in the adrenaline group vs. £2698 (€3103) in the
placebo group [unadjusted mean cost difference £1091
(€1255) (bootstrap 95% CI £807 (€928) to £1398
(€1608)); P < 0.001] (Table 2). There was also a signifi-
cant difference in mean total societal costs: £3829
(€4403) in the adrenaline group vs. £2687 (€3090) in the
placebo group [unadjusted mean cost difference £1143
(€1314) (bootstrap 95% CI £861 (€990) to £1451
(€1669)); P < 0.001]. Amongst those who survived to
hospital discharge, there were no significant differences
in mean total NHS and PSS costs. However, amongst
survivors to hospital discharge, mean utility values were
significantly lower at hospital discharge in the adrenaline
group [0.48 vs 0.60, unadjusted mean difference − 0.118
(95% CI − 0.196 to − 0.032); P = 0.002].
The within-trial economic evaluation results are sum-
marised in Table 3. The base case analysis, over a 6-
month time horizon, produced an ICER of £1,693,003 (€1,
946,953) per QALY gained, reflecting significantly higher
mean costs and only marginally higher mean QALYs in
the adrenaline group. Extrapolating the within-trial ana-
lysis produced ICERs of £644,308 (€740,954) per QALY
gained over 1 year and £81,070 (€93,231) per QALY
gained over the lifetimes of survivors. The probability that
adrenaline is cost-effective remained below 1% across a
range of cost-effectiveness thresholds (plots a and b of
Fig. 3), while mean net monetary benefits were negative at
all thresholds. The cost-effectiveness estimates remained
robust to a range of sensitivity and subgroup analyses
(Additional file 7).
The decision-analytic modelling that estimated com-
bined direct economic effects over the lifetimes of survi-
vors and indirect economic effects in organ recipients
revealed that routine use of adrenaline at a UK-wide
level in this patient group would result in incremental
costs of £49,759,481 (€57,223,403) and 3093 additional
QALYs per annum (Table 4). The mean ICER at a
patient-level was estimated at £16,086 (€18,499) per
QALY gained for adrenaline. The probability that adren-
aline is cost-effective compared with placebo was 39% at
a £15,000 (€17,250) per QALY cost-effectiveness thresh-
old, increasing to 90% at a £30,000 (€34,500) threshold
(Table 4 and plot c of Fig. 3). Sensitivity analyses re-
vealed that these cost-effectiveness estimates remained
robust to a range of modelling assumptions and data in-
puts with the exception of the estimated impact of the
number of organs donated for transplantation on the
cost-effectiveness of adrenaline (Additional file 5).
Discussion
This paper presents the first economic evaluation of
adrenaline in adults with out-of-hospital cardiac arrest.
The study revealed that when the assessment is re-
stricted to the first 6 months that follow out-of-hospital
Fig. 2 Flow chart of data sources used to inform resource use and costs. S2HD indicates survivors to hospital discharge, HES/PEDW indicates
Hospital Episode Statistics/Patient Episode Database for Wales
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Table 1 PARAMEDIC2 organ donor and recipient information
Placebo Adrenaline Total P value
Number of recipients 67 99 166
Number of organs donated 74 115 189
Gender of donor Males 14 (58.3%) 24 (60.0%) 38 (59.4%) 0.895
Females 10 (41.7%) 16 (40.0%) 26 (40.6%)
Gender of recipient Males 37 (55.2%) 61 (61.6%) 98 (59.0%) 0.411
Females 30 (44.8%) 38 (38.4%) 68 (41.0%)
Age of the recipient < 18 4 (6.0%) 5 (5.1%) 9 (5.4%) 0.748
18–30 6 (9.0%) 6 (6.1%) 12 (7.2%)
31–50 25 (37.3%) 30 (30.3%) 55 (33.1%)
51–60 15 (22.4%) 32 (32.3%) 47 (28.3%)
61–70 14 (20.9%) 22 (22.2%) 36 (21.7%)
> 70 3 (4.5%) 4 (4.0%) 7 (4.2%)
Average number of organs (per donor) N1 24 40 64
Mean 3.1 2.9 3.0 0.584
Median 3 3 3
Std 1.6 1.2 1.4
Min-max 1–7 1–6 1–7
Missing 0 0 0
Type of organs (n) Kidney only 39 (58.2%) 54 (54.5%) 93 (56.0%) 0.457
En-bloc kidney 0 (0.0%) 0 (0.0%) 0 (0.0%)
Double kidney 0 (0.0%) 5 (5.1%) 5 (3.0%)
Heart only 3 (4.5%) 4 (4.0%) 7 (4.2%)
Liver only 16 (23.9%) 24 (24.2%) 40 (24.1%)
Pancreas only 2 (3.0%) 0 (0.0%) 2 (1.2%)
Single lung 0 (0.0%) 1 (1.0%) 1 (0.6%)
Double lung 3 (4.5%) 3 (3.0%) 6 (3.6%)
Liver and kidney 1 (1.5%) 1 (1.0%) 2 (1.2%)
Kidney and pancreas 3 (4.5%) 7 (7.1%) 10 (6.0%)
1N refers to the number of donors in adrenaline and placebo groups
Table 2 Total costs in 2017 prices by trial arm
Assessment
period
Category Adrenaline (n = 4015) Placebo (n = 3999) Adrenaline versus placebo
N Mean (SE), £ N Mean (SE), £ Mean cost difference
(bootstrap 95% CI), £
P value
0–6 months Hospitalisation costs (NHS and PSS) 4006 2669 (179) 3988 1460 (129) 1209 (804, 1660) < 0.001
Non-hospitalisation costs (NHS and PSS) 3934 1785 (21) 3926 1678 (13) 107 (61, 155) < 0.001
Non-NHS and PSS costs 3956 51 (15) 3952 15 (6) 36 (8, 69) 0.01
Total NHS and PSS costs 3934 3789 (121) 3926 2698 (94) 1091 (807, 1398) < 0.001
Total societal costs 3933 3829 (124) 3925 2687 (92) 1143 (861, 1451) < 0.001
Data are for all patients and based on combined HES© and CRF data. Copyright© (2019), the Health and Social Care Information Centre. Re-used with the
permission of the Health and Social Care Information Centre [and/or [name of licensor]]. All rights reserved
CI confidence interval, N number of participants with complete data (zero utilisation and costs assigned to deaths), NHS National Health Service, PSS Personal
Social Services, SE standard error
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cardiac arrest, adrenaline is associated with significantly
higher mean costs, largely driven by the additional costs
associated with hospital admissions, and only marginally
higher mean QALYs. The base case analysis generated a
mean ICER of £1,693,003 (€1,946,953) per QALY gained
at 6 months post-randomisation, well in excess of ac-
cepted cost-effectiveness thresholds [11]. Consequently,
the probability that adrenaline is cost-effective approxi-
mated to zero in the base-case analysis. Moreover, this
conclusion remained robust after extensive sensitivity
Fig. 3 The three graphs on the left-hand side represent the cost-effectiveness plane for the within-trial, lifetime and the combined cardiac arrest
and organ donor analyses. The three graphs on the right-hand side represent cost-effectiveness acceptability curves and give the probability that
adrenaline is cost-effective compared with placebo at a specified cost-effectiveness threshold. Each cost-effectiveness plane is divided into four
quadrants (North-West, North-East, South-West and South-East) by the intersection of the horizontal and vertical axis. South-East quadrant implies
adrenaline is less costly and more effective than placebo, North-West quadrant implies adrenaline is less effective and more costly, the North-East
quadrant implies adrenaline is more effective but also more costly and the South-West quadrant implies adrenaline is less effective but also
less costly
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analyses that accounted for different sources of uncer-
tainty. Notably, however, separate decision-analytic
modelling that extrapolated cost-effectiveness over the
lifetimes of survivors and incorporated additional
costs and health consequences for organ recipients
significantly altered the cost-effectiveness calculus.
The probability that adrenaline is cost-effective in-
creased to 90% at a £30,000 (€34,500) per QALY
cost-effectiveness threshold, arguably within the
bounds of acceptance by health technology agencies
tasked with reimbursement decisions [11]. The cost-
effectiveness conclusions were particularly sensitive to
the inclusion of recipients of donated organs into
economic modelling. The economic value of the add-
itional survival and QALY benefits to organ recipients
associated with adrenaline clearly outweigh the add-
itional costs that result from organ transplantation.
Similar findings have been reported for other inter-
ventions. In a study evaluating the costs and benefits
of traumatic cardiopulmonary arrest resuscitation
[27], the authors concluded that the financial burden
associated with the procedure could be offset by
expanding the benefits to include organ donation.
Previous economic evaluations of adrenaline were
conducted in clinical contexts outside the manage-
ment of out-of-hospital cardiac arrest [28–30], and
therefore, a comparative assessment of cost-
effectiveness evidence is not possible. Similarly, other
pharmacological interventions for cardiac arrest, such
as anti-arrythmics, have yet to be evaluated from an
economic perspective. Our data should, therefore, be
of relevance to clinical decision-makers and service
planners tasked with the care and management of a
condition that causes significant death and disability.
Moreover, our economic evaluation is the first, to
our knowledge, that has modelled the indirect eco-
nomic benefits of organ donation arising from an
intervention that increases the likelihood of admis-
sion to intensive care following an acute out-of-
hospital clinical event. It may, therefore, alter meth-
odological thinking on the incorporation of benefits
other than directly to the patient into economic
evaluations of interventions that affect the likelihood
for organ donation. Such a methodological shift will
require ethical consideration of how to balance ben-
efits to others with benefits or harms to patients re-
ceiving the intervention.
Readers should consider caveats when interpreting
the study results. First, our findings may not be ap-
plicable outside of the UK as the models of prehos-
pital care, and healthcare costs may differ in other
countries. Second, our adapted model of adult lung
transplantation excluded the effects of adrenaline on
pancreas and heart transplants. A paucity of
epidemiological and economic evidence meant that
we were unable to parameterise extensions to our
decision-analytic model that considered effects be-
yond lung, liver and kidney transplants. Nevertheless,
the number of pancreases and hearts transplanted to
recipients of organs donated by the PARAMEDIC2
patients was small (< 10) and therefore unlikely to
alter the balance of overall conclusions. Third, as
with any health economic evaluation, there are likely
to be potentially relevant effects that are not cap-
tured by the tools available for measurement and
valuation. Specifically, we did not value other poten-
tial consequences of adrenaline, for example, the po-
tential benefits to family members arising from the
increased likelihood of being able to say goodbye
and be present at the time of death [31]. Finally, in
the modelling that extended our assessments of cost-
effectiveness of adrenaline over the lifetimes of car-
diac arrest survivors and incorporated the indirect
economic effects of organ transplantation, a number
of assumptions were required to simplify the param-
eterisation and address data limitations. Details of
these assumptions are described in additional file 5.
These included assuming that functional health state
does not change over extended periods of survival
and that resource use captured in the 3–6 month
post-randomisation period can be extrapolated to
cover the 6–12 month post-randomisation period.
The organ donor modelling required a set of steady
or equilibrium-state assumptions (number of organs
available each year equals the number of transplanta-
tions with no wastage; the probability of death or re-
moval on the waiting list are independent of organ
supply) that captured the impact of intervention on
the probability of transplantation. Nevertheless, our
approach was consistent with current methodological
guidance for decision-analytic modelling [32]. Fur-
thermore, extensive sensitivity analyses were con-
ducted that found that the conclusions from the
base-case analyses were robust to doubling and halv-
ing input parameter values and alternative specifica-
tions of modelling assumptions.
Conclusion
In conclusion, adrenaline use in adults with out-of-
hospital cardiac arrest does not represent a cost-effective
use of resources when only directly related costs and
consequences are considered. However, incorporating
the indirect economic effects associated with trans-
planted organs substantially alters the cost-effectiveness
calculus, suggesting decision-makers should consider the
complexity of direct and indirect economic impacts of
adrenaline.
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